Last reviewed 2026-04-23 · How we verify

MP513

MP513 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.

MP513 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Chronic obstructive pulmonary disease (COPD).

At a glance

Mechanism of action

PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce airway inflammation and improve lung function in obstructive airway diseases.

Approved indications

• Chronic obstructive pulmonary disease (COPD)

Common side effects

• Nausea
• Diarrhea
• Headache
• Tremor

Key clinical trials

• Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes (PHASE3)
• Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes (PHASE2)
• Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin) (PHASE3)
• Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin) (PHASE3)
• Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes (PHASE3)
• Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes (PHASE3)
• Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients (PHASE3)
• Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.